

Disclosure policy

September 2010



Mediq strives to provide complete, correct, timely and consistent information to investors and other stakeholders of the company, as well as to analysts, financial institutions and the media. In doing so, Mediq aims to present an accurate overview of its activities, past results and future expectations.

As a listed company, Mediq accepts its responsibility to ensure that all its statements are in line with the regulations and responsibilities defined by Euronext Amsterdam and the Netherlands Authority for the Financial Markets.

The guidelines apply to all employees of Mediq.

This policy has been distributed throughout the organisation and is reviewed at least once a year. The most recent version is also always available on the Mediq intranet (<http://1.mediq.com>).

Contents

Introduction	3
Framework	3
Disclosure policy	4
Price-sensitive information	4
Publication of price-sensitive information	4
Company spokespersons	4
Contacts with investors, analysts and the press	5
Analyst reports	6
Meeting embargo	6
Policy on forecasts and guidance	6
Policy on rumours	6
Contact	7

Introduction

Mediq strives to provide complete, correct, timely and consistent information to investors and other stakeholders of the company, as well as to analysts, financial institutions and the media. In doing so, Mediq aims to present an accurate picture of its activities, past results and future expectations.

With this disclosure policy ("policy"), Mediq wishes to achieve the following objectives:

- Compliance with the regulations and obligations related to its listing on Euronext Amsterdam, as contravening these regulations can result in considerable financial damage to Mediq and its employees, and/or possibly harm the company's good name.
- Clarify the way in which Mediq publishes information and presents it to investors, financial analysts and journalists.
- Increase the awareness of management and employees regarding the obligations and practices of publishing information.

Framework

As a listed company, Mediq accepts its responsibility to ensure that all its statements are truthful and accurate, generally accessible and in line with the regulations and responsibilities defined by Euronext Amsterdam and the Netherlands Authority for the Financial Markets. In general, Mediq aims for an active and open dialogue with stakeholders so that they obtain a complete, accurate and unambiguous understanding of the company's past results as well as of its prospects.

This policy applies to all employees of Mediq and all other natural persons that are linked to Mediq in a professional capacity ("employees"). In its application to employees, the policy concerns not only their activities at Mediq, but also any other activities insofar as they could affect the good name of Mediq (for example, as an office holder of an industry association).

The policy extends to written and verbal communications with members of the investment community and the media. Written communications include documents filed with the AFM, the annual report, press releases, presentations and information published on the company's website; verbal communications include statements made at press conferences, group meetings and one-on-one discussions with analysts, investors and/or journalists.

Disclosure policy

Price-sensitive information

As a listed company, Mediq is obliged to publish price-sensitive information without delay by means of press releases. Price-sensitive information is specific information that has not yet been made public and could have a significant effect on the share price. Falling within this scope by definition is the publication of results. Other examples are significant facts concerning the company's strategy, capital and control.

Mediq delays the publication of price-sensitive information only if this is justified in the interests of the company, does not cause the general public to receive a false picture of the company's situation and the confidentiality of the information can be guaranteed. Mediq has a regulation on insider information that forbids Employees to share such information with third parties. (This is a legal prohibition, which includes the possibility to impose sanctions under labour law). If the confidentiality of a particular item of price-sensitive information can no longer be guaranteed, it is immediately made public.

Publication of price-sensitive information

Mediq publishes information it regards as price-sensitive in the form of a press release. A draft of the press release is prepared by the Corporate Communications Director and published only after the required internal approvals have been received. In all cases, this means at least from the CEO and CFO.

Press releases are issued through the Netherlands Authority for the Financial Markets and Euronext Amsterdam, sent to investors, analysts, journalists and news services, and published on Mediq's website, so that all stakeholders receive the information at the same time.

Press releases are always published in Dutch and English. They are sent out preferably before the stock exchange opens or after it closes. The financial calendar on Mediq's website gives advance notice of when results are to be made public.

Company spokespersons

As part of their day-to-day work, employees regularly communicate with customers and suppliers, among other persons, via presentations, congresses and articles in professional journals. This disclosure policy should not hinder them in this respect. However, they have to avoid communicating price-sensitive information or making other statements incorrectly that could harm the good name of Mediq.

With that in mind, the rules are as follows:

- The general rule is that all contact with the press is conducted through the Mediq press officer (employed by Corporate Communications).
- Only the members of the Management Board, the Corporate Communications Director (who is also responsible for Investor Relations) and a Mediq press officer (employed by

Corporate Communications) are always authorised to address investors, analysts and journalists on behalf of the company.

- Only where the marketing activities of the business unit is concerned, the management of a business unit can follow its own media policy. The Guidelines for dealing with the Press need to be observed at all times.
- Every business unit located outside of the Netherlands is obliged to have its own spokesperson as a contact for the local press.

Authorised spokespersons (as described at the second bullet point) may request other employees (often senior management) to provide information to interested parties in the finance industry or the media. This will take place in the presence of an authorised spokesperson, the Mediq press officer.

Contacts with investors, analysts and the press

In accordance with the above, Mediq will not give price-sensitive information to any person or group before issuing a press release. Should this happen inadvertently, a press release will be issued immediately. In all cases of doubt concerning the price sensitivity of information to be provided, the Corporate Communications Director should be consulted.

Presentations to groups of analysts are announced in advance and can be followed live via a webcast, which is subsequently filed on the website. Press conferences are also announced in advance on the website. Presentation handouts for analysts and investors are published on the company's website when the presentation is given.

Presentations to groups of private and institutional investors are given regularly and generally announced on the website. Other meetings with analysts and investors are not usually announced in advance, nor can they be followed via a webcast or in any other way. Such meetings involve discussions only of information that is already in the public domain. Information already published by Mediq, and hence in the public domain, can be discussed by authorised spokespersons one-on-one with interested parties. At these meetings, information not in the public domain and not price-sensitive can be provided if this helps to increase the recipients' understanding of the company. Such information is usually factual and not of a speculative nature.

Mediq will provide access to its senior management, usually the Management Board, to the extent this is possible. Professionals of financial institutions will have access at least to Corporate Communications. Requests for meetings with Mediq's senior management will be complied with as much possible, workload permitting. Whether such requests are granted depends on several factors, including the number of shares an investor holds, the knowledge an analyst or investor already has of the company and its industry, and the extent to which an analyst or investor has already had access to company management.

Mediq will never refuse an analyst or investor access because of a negative opinion about the company's shares or because of a decision to sell them.

Analyst reports

Mediq encourages analysts to adopt a wide perspective for research, so that investors can obtain a deeper understanding of the company.

On request, Mediq will review and comment on analysts' draft reports, but only to ensure that information in the public domain is not reported incorrectly. Under no circumstances will the Corporate Communications Director, members of the Management Board or other employees comment on opinions about the company's prospects or other financial projections, apart from referring to the information on the subject already published by Mediq.

Mediq never pays financial institutions to write research reports.

As analyst reports are the property of the body that publishes them, Mediq never distributes such reports, including via its website.

'Silent' (meeting embargo) period

No meetings are held with analysts or investors during the three weeks preceding publication of the first, second and third quarter results and the four weeks preceding publication of the fourth quarter results.

This silent (meeting embargo) period is not the same as the 'closed' (trading embargo) period during which there is a prohibition on the buying and selling of shares by employees subject to the insider-trading regulation (see separate regulation on this).

Policy on forecasts and guidance

Market conditions permitting, Mediq will publish forecasts in the form of press releases, usually as part of the publication of its figures. Any amendments to or confirmations of these forecasts are published in the form of press releases. Under no circumstances will the Corporate Communications Director or any other employee provide parties with more information than in the most recently published forecasts.

Policy on rumours

As a rule, employees, including authorised spokespersons, when responding to questions about market rumours should state: "We do not react to market rumours." As an exception, it might be necessary to react to a rumour if it is having a significant impact on the share price. If it is decided to react, this will be in the form of a press release.

Contact

For requests please contact Catrien van Buttingha Wichers,
Director Corporate Communications Mediq, on +31 (0)30 - 282 16 09
or via catrien.van.buttingha@mediq.com